Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311314 | 0.96 | DAO (0.32) | DAOF7F3FLT3KDM4E | |
| Potassium Ion SCHEMBL1311794 | 0.96 | DAO (0.32) | DAOF7F3FLT3KDM4E | |
| Lithium Ion SCHEMBL1310748 | 0.71 | FLT3 (0.31) | DAOFLT3KDM4EMAPTHPGD | |
| Potassium Ion SCHEMBL1313325 | 0.68 | FLT3 (0.31) | DAOFLT3KDM4EMAPTHPGD | |
| Lithium Ion SCHEMBL1311978 | 0.68 | DAO (0.31) | DAO | |
| Indole-2-Carboxylic Acid SCHEMBL31078830 | 0.67 | FLT3 (0.69) | DAOFLT3KDM4EMAPTHPGD | |
| SCHEMBL1311322 | 0.64 | DAO (0.31) | DAO | |
| Potassium Ion SCHEMBL1311482 | 0.64 | DAO (0.31) | DAO | |
| Lithium Ion SCHEMBL1310040 | 0.63 | DAO (0.31) | DAO | |
| Indole-2-Carboxylic Acid SCHEMBL30949478 | 0.63 | FLT3 (0.69) | DAOFLT3KDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297167-A1 | SELENOPHENE AND SELENAZOLE CARBOXYLIC ACID DERIVATIVES | Ironwood Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | DAO 1/4885F7 4216/4885F3 3758/4885 |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | DAO 1/4885F7 4216/4885F3 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.